Portrait of Flores, Bill

Flores, Bill

U.S. Representative TX-17 Republican Party

Congressional stock trade history disclosed under the STOCK Act, as filed.

Disclosed trades
830
Buys / sells
37% / 63%
Last trade
Dec 31, 2019
Last filing
Jan 9, 2020

Latest disclosed trades

Latest 10 of 830
Ticker Type Traded
— salient MlP Fund [HN] F IlINg s Sell Dec 31, 2019
SPN Buy Dec 19, 2019
— Hyatt Hotels Corp Notes; 03/15/2 Buy Dec 6, 2019
— salient MlP Fund, lP [HN] F IlIN Sell Nov 30, 2019
IBM Buy Oct 2, 2019
AVGO Sell Oct 2, 2019
COP Sell Sep 19, 2019
GILD Buy Sep 19, 2019
LUV Sell Sep 19, 2019
WBA Buy Sep 19, 2019

Amounts are reported as STOCK Act range buckets, not exact dollar values. Trade dates are the date the politician executed the trade; filing dates are when the disclosure was filed. Sign up to filter by ticker, amount range, or filing window.

Flores, Bill stock trade activity

FilingIQ has indexed 830 congressional stock trade disclosures for Flores, Bill. The most recent disclosed transaction is dated Dec 31, 2019.

Across the full history, 305 purchases and 524 sales have been disclosed under the STOCK Act.

Top tickers traded by Flores, Bill

Frequently asked

How many stock trades has Flores, Bill disclosed?
FilingIQ tracks 830 Periodic Transaction Report disclosures for Flores, Bill, with the most recent dated Dec 31, 2019. Every entry sources back to the official House Office of the Clerk or Senate Office of Public Records.
Is Flores, Bill a net buyer or net seller?
Across the disclosed trade history, 305 (37%) were purchases and 524 (63%) were sales. Compensation and exchanges are filtered out of these counts.
Where does FilingIQ's data on Flores, Bill come from?
Every trade shown on this page is sourced from the STOCK Act disclosures filed with the House or Senate. FilingIQ normalizes ticker resolution, dates, and amount brackets across both chambers.

Methodology & sources

Disclosures parsed from official House Office of the Clerk and Senate Office of Public Records filings. Methodology documented on methodology. Compiled by Thomas Kraaibeek. Not investment advice; see disclaimer.